CareDx Expands Specialty Oncology Diagnostics with Naveris Acquisition
NTRA•CareDx announced acquisition of privately held Naveris, a developer of ctDNA-based oncology assays, to bolster its specialty oncology diagnostics portfolio. The deal, terms undisclosed, extends CareDx’s product offerings into a market projected to grow at double-digit annual rates, strengthening its revenue diversification beyond transplant testing.
1. Acquisition Announcement
CareDx announced on July 2 that it has acquired Naveris, a privately held developer of circulating tumor DNA-based oncology assays. Terms of the transaction were not disclosed.
2. Strategic Rationale
The acquisition adds Naveris’s liquid biopsy technology to CareDx’s existing diagnostic platform, expanding the company’s footprint beyond transplant diagnostics into high-growth specialty oncology testing.
3. Market Outlook
The specialty oncology diagnostics market is expected to grow at a double-digit compound annual growth rate over the next five years, positioning CareDx to capture new revenue streams and enhance long-term growth prospects.
